Related Experiment Videos
Esophageal perforation after fiberoptic variceal sclerotherapy
Insights
Perforation after fiberoptic sclerotherapy occurs in 1-6% of patients, typically 2-14 days post-procedure due to chemical necrosis. A cautious approach is recommended for Child
Area of Science:
- Gastroenterology
- Endoscopic Procedures
Background:
- Fiberoptic sclerotherapy is a common treatment for esophageal conditions.
- Esophageal perforation is a known complication of sclerotherapy.
Observation:
- Perforation incidence ranges from 1-6% per patient.
- Perforation occurs 2-14 days post-procedure.
- Chemical necrosis of the esophageal wall causes perforation.
Findings:
- Risk of perforation is elevated in Child's class C patients.
- High volumes or concentrations of sclerosant increase perforation risk.
- Limiting sclerotherapy to two sessions within 2 weeks and using ≤10 ml of 1.5% sodium tetradecyl sulfate per session may reduce risk.
Implications:
- Clinical guidelines should incorporate cautious sclerotherapy protocols for high-risk patients.
- Further research may explore alternative sclerosants or techniques to minimize perforation.
- Patient outcomes can be improved by mitigating this serious complication.
Abstract:
Our experience and review of the literature suggests that perforation follows fiberoptic sclerotherapy at an incidence of 1-6% per patient. Perforation is delayed for 2-14 days after the procedure and is due to chemical necrosis of the esophageal wall. The risk of perforation is higher in Child's class C patients. The use of large volumes or high concentrations of sclerosant may increase the risk of perforation. To reduce this risk, we suggest a cautious approach to Child's class C patients, with no more than two sclerosis sessions during the first 2 weeks of treatment using less than or equal to 10 ml of 1.5% sodium tetradecyl sulfate per session.